<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011019</url>
  </required_header>
  <id_info>
    <org_study_id>AL2846-Ib-01</org_study_id>
    <nct_id>NCT05011019</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis</brief_title>
  <official_title>Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AL2846 is a multi-target receptor tyrosine kinase inhibitor. The purpose of this study is to&#xD;
      evaluate the safety and efficacy of AL2846 capsules in Chinese patients with type I&#xD;
      neurofibromatosis (NF1) (neurofibromas and malignant peripheral nerve sheath tumors).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>:Baseline up to 96 weeks</time_frame>
    <description>The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>objective response rate (ORR)</measure>
    <time_frame>Baseline up to 96weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II clinical recommended dose （RP2D）</measure>
    <time_frame>Baseline up to 96 weeks</time_frame>
    <description>recommended dose of Phase II clinical trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>The time when the participants first achieved complete or partial remission to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS rate of one year</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Rate of patients with PFS reaching one year among all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival（OS）</measure>
    <time_frame>assessed up to100 months</time_frame>
    <description>From date of first administration of test drug until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale (self-report form)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Self-report of pain in target tumor and other parts of body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life related scale（European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire version 3.0, EORTC QLQ-C30(V3)）</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Questionnaires about the quality of life (including mental state, appetite state, sleep, etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient's overall impression of the severity of symptoms (self-report)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Self-report on the severity of tumor pain, overall pain status, and tumor-related problems other than pain (vision, hearing, mobility, hearing, appearance, etc.)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors</condition>
  <arm_group>
    <arm_group_label>AL2846 Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the dose escalation phase, patients enrolled in the group will first receive a single fasting administration（AL2846 capsules 120-150mg，oral）. The observation period is 3 days. If dose-limited toxity (DLT) does not occur, they will continue to receive multiple consecutive fasting administrations (120mg-150mg，once a day，oral ),every 28 days as a treatment cycle.&#xD;
During the dose expansion phase, patients will receive multiple consecutive fasting administrations (AL2846 capsules，120mg-150mg, oral ), every 28 days as a treatment cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL2846 capsules</intervention_name>
    <description>AL2846 is a multi-target receptor tyrosine kinase inhibitor.</description>
    <arm_group_label>AL2846 Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who voluntarily join the study and sign the informed consent form;&#xD;
&#xD;
          -  Aged 18 to 75 years (when signing informed consent); Eastern cooperative oncology&#xD;
             group（ ECOG） score: ≤2 ; patients with malignant peripheral nerve sheath tumors&#xD;
             （MPNST）who are expected to survive ≥12 weeks;&#xD;
&#xD;
          -  NF1 patients (including patients with MPNST) who are judged by the investigator as&#xD;
             incomplete surgical resection, require systemic treatment, and have measurable&#xD;
             lesions;&#xD;
&#xD;
        Note: NF1 diagnostic criteria meets at least one of the following:&#xD;
&#xD;
          1. Genetic examination confirmation: test positive for NF1 germline mutation in a&#xD;
             Clinical Laboratory Improvement Amendments （CLIA）-certified laboratory (positive NF1&#xD;
             germline mutation must be confirmed by the central laboratory of this project, or an&#xD;
             NF1 mutation test report issued by a CLIA-certified laboratory;&#xD;
&#xD;
          2. Clinical and imaging examination confirmation: According to the clinical National&#xD;
             Institute of Health (NIH) consensus criteria, at least two of the following NF1&#xD;
             diagnostic criteria are met:&#xD;
&#xD;
               1. Six or more café-au-lait macules (≥0.5cm in prepubertal patients or ≥1.5 cm in&#xD;
                  post pubertal patients)&#xD;
&#xD;
               2. Freckling in axilla or groin&#xD;
&#xD;
               3. ≥2 neurofibromas of any type, or ≥1 plexiform neurofibromas&#xD;
&#xD;
               4. Optic glioma&#xD;
&#xD;
               5. Two or more Lisch nodules&#xD;
&#xD;
               6. A distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia or&#xD;
                  thinning of long bone cortex)&#xD;
&#xD;
               7. A first-degree relative with NF1&#xD;
&#xD;
                  - Patients who are confirmed by direct measurement or according to the Response&#xD;
                  Evaluation Criteria in Solid Tumors（RECIST） 1.1 standard that there is at least&#xD;
                  one evaluable lesion, and the diameter of the lesion is greater than 3 cm, and&#xD;
                  the lesion can be seen in three consecutive sections;&#xD;
&#xD;
                    -  The main organs function well and meet the following standards:&#xD;
&#xD;
          1. Blood routine examination standard (no blood transfusion and no hematopoietic&#xD;
             stimulating factor drugs used for correction within 7 days before the examination):&#xD;
&#xD;
             a. White blood cell count (WBC) ≥3.5×109/L b. Hemoglobin (HGB) ≥90 g/L; c. The&#xD;
             absolute value of neutrophils (NEUT) ≥ 1.5×109/L; d. Platelet count (PLT) ≥ 100×109/L.&#xD;
&#xD;
          2. The biochemical inspection shall meet the following standards:&#xD;
&#xD;
             a. Albumin (ALB) ≥35g/L; b. Total bilirubin (TBIL) ≤ 1.5× the upper limit of normal&#xD;
             (ULN), and patients with Gilbert syndrome are ≤ 2.5× ULN; c. Alanine-based transferase&#xD;
             (ALT) and aspartate-based transferase (AST) ≤2.5×ULN; d. Serum creatinine (CR)&#xD;
             ≤1.5×ULN or creatinine clearance (CCR) ≥50ml/min (application of standard&#xD;
             Cockcroft-Gault formula);&#xD;
&#xD;
          3. The coagulation function test shall meet the following standards:&#xD;
&#xD;
             International normalized ratio (INR)≤1.5×ULN (have not received anticoagulant&#xD;
             therapy);&#xD;
&#xD;
          4. Thyroid function examination must meet the following standards:&#xD;
&#xD;
        Thyroid-stimulating hormone (TSH)≤ULN; if abnormal, Triiodothyronine （T3） and&#xD;
        thyroxine（T4）levels should be examined, and T3 and T4 levels are normal.&#xD;
&#xD;
        5. Heart color Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF)&#xD;
        ≥50%.&#xD;
&#xD;
        - Female patients of childbearing age should agree to use contraceptive measures (such as&#xD;
        intrauterine devices, contraceptives or condoms) during the study period and within 6&#xD;
        months after the end of the study; serum pregnancy test within 7 days before study entry&#xD;
        Negative, and must be a non-lactating subject; male patients should agree to adopt&#xD;
        avoidance measures during the study period and within 6 months after the end of the study&#xD;
        period;&#xD;
&#xD;
        - Patients enrolled in the second stage need to be pathologically confirmed to be enrolled&#xD;
        in cohort 1, cohort 2 or cohort 3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Combined diseases and medical history:&#xD;
&#xD;
             1. Patients who have other malignant tumors within 3 years before the first medication&#xD;
             or are currently suffering from other malignancies. The following two situations can&#xD;
             be enrolled: other malignant tumors treated by a single operation; achieving 5&#xD;
             consecutive years of disease-free survival (DFS);&#xD;
&#xD;
             2. With factors that affect oral medications (such as dysphagia, chronic diarrhea and&#xD;
             intestinal obstruction, etc.)&#xD;
&#xD;
             3. Unreliable toxic reactions higher than Common Terminology Criteria for Adverse&#xD;
             Events(CTCAE) v5.0 level 1 caused by any previous treatment, excluding hair loss;&#xD;
&#xD;
             4. Received major surgical treatment or obvious traumatic injury within 28 days before&#xD;
             the first medication;&#xD;
&#xD;
             5. Long-term unhealed wounds or fractures caused by surgery or trauma;&#xD;
&#xD;
             6. Arterial/venous thrombosis occurred within 6 months before the first medication,&#xD;
             such as cerebrovascular accident (including temporary ischemic attack, cerebral&#xD;
             hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;&#xD;
&#xD;
             7. With a history of psychotropic drug abuse and cannot be quit or have mental&#xD;
             disorders;&#xD;
&#xD;
             8. There are risk factors for prolonging the corrected QT interval（QTc）interval, such&#xD;
             as uncorrectable hypokalemia, hereditary long QT syndrome, or taking drugs that&#xD;
             prolong the QTc interval (mainly class Ia, Ic, and III antiarrhythmic drugs) ；&#xD;
&#xD;
             9. Past or current retinal vein stenosis, retinal detachment, central retinal vein&#xD;
             occlusion, glaucoma, grade 1 cataract, related symptoms caused by the disease are not&#xD;
             considered as exclusion criteria;&#xD;
&#xD;
             10. Interstitial pneumonia, including clinically significant radiation pneumonia;&#xD;
&#xD;
             11. Patients with any severe and/or uncontrollable disease, including:&#xD;
&#xD;
               1. Unsatisfactory blood pressure control (systolic blood pressure ≥150 mmHg or&#xD;
                  diastolic blood pressure ≥100 mmHg);&#xD;
&#xD;
               2. Suffering from grade ≥2 myocardial ischemia or myocardial infarction, arrhythmia&#xD;
                  (including male QTc ≥450 ms (male), QTc ≥470 ms (female)) and grade ≥2 congestive&#xD;
                  heart failure (New York Heart Association ( NYHA) classification, appendix 2);&#xD;
&#xD;
               3. Active or uncontrolled serious infection (≥CTCAE v5.0 Grade 2 infection);&#xD;
&#xD;
               4. Active hepatitis: hepatitis B reference: HBsAg is positive, and the HBV DNA test&#xD;
                  value exceeds the upper limit of normal; hepatitis C reference: HCV antibody is&#xD;
                  positive, and the HCV virus titer test value exceeds the upper limit of normal;&#xD;
                  Note: Those who meet the criteria for entry, hepatitis B surface antigen-positive&#xD;
                  or core antibody-positive patients, and hepatitis C patients need to continue&#xD;
                  antiviral therapy to prevent virus activation;&#xD;
&#xD;
               5. Renal failure requiring hemodialysis or peritoneal dialysis;&#xD;
&#xD;
               6. A history of immunodeficiency, including HIV positive or other acquired or&#xD;
                  congenital immunodeficiency diseases, or a history of organ transplantation;&#xD;
&#xD;
               7. Poor diabetes control (fasting blood glucose (FBG)&gt; 10 mmol/L);&#xD;
&#xD;
               8. Urine routines suggest that urine protein is ≥++, and the 24-hour urine protein&#xD;
                  quantification is confirmed to be &gt;1.0 g;&#xD;
&#xD;
               9. Those who suffer from epilepsy and need treatment;&#xD;
&#xD;
          -  Tumor-related symptoms and treatment:&#xD;
&#xD;
             1. Have received surgery, chemotherapy, radiotherapy or other anti-cancer therapies&#xD;
             within 4 weeks before the first medication (the washout period will be calculated from&#xD;
             the end of the last treatment); Note: Those who have received local radiotherapy in&#xD;
             the past can be included in the group if the following conditions are met: the end of&#xD;
             radiotherapy is more than 4 weeks from the beginning of the study treatment (brain&#xD;
             radiotherapy is more than 2 weeks); and the target lesion selected for this study is&#xD;
             not in the radiotherapy area; Or the target lesion is located in the radiotherapy&#xD;
             area, but the progress has been confirmed.&#xD;
&#xD;
             2. Have received National Medical Products Administration(NMPA) approved Chinese&#xD;
             patent medicines with anti-tumor indications (including compound cantharidin capsules,&#xD;
             Kangai injections, Kanglaite capsules/injections, Aidi injections, Brucea javanica oil&#xD;
             injections). /Capsules, Xiaoaiping Tablets/Injections, Huachansu Capsules, etc.)&#xD;
             treatment;&#xD;
&#xD;
          -  Research and treatment related:&#xD;
&#xD;
               1. Patients who have previously received one of the following treatments:&#xD;
&#xD;
                  a. Patients who have received NF1 drug treatment within 3 months before&#xD;
                  enrollment, and the related side effects have not yet recovered to below grade 1&#xD;
                  (except for hair loss). Note: Patients who are receiving NF1 drug treatment must&#xD;
                  recover from the acute toxicity of the current NF1 treatment to less than or&#xD;
                  equal to Grade 1 (refer to CTCAE v5.0) before entering this study; b. Patients&#xD;
                  Received tipifarnib, pirfenidone, peg-interferon, sorafenib or other VEGFR&#xD;
                  inhibitor or biological treatments within 14 days before receiving study drug&#xD;
                  treatment ; c. Receiving strong Cytochrome P450 3A4 enzyme（CYP3A4） inhibitors&#xD;
                  (amprenavir, atazanavir, boceprevir, clarithromycin, cornivatan, delavirdine,&#xD;
                  diltiazem, erythromycin) within 14 days before receiving study drug treatment ,&#xD;
                  Fursanavir, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Mibefradil,&#xD;
                  Miconazole, Nefazodone, Nefinavir, Posaconazole, Ritonavir, saquinavir,&#xD;
                  tilarrevir, telithromycin, verapamil, voriconazole, etc.) or strong inducers&#xD;
                  (carbamazepine, felbamate, nevirapine, phenobarbital, phenytoin, Patients with&#xD;
                  primidone, rifabutin, rifampicin, rifapentin, etc.), except for external use on&#xD;
                  the skin;&#xD;
&#xD;
               2. Unable to perform Magnetic Resonance Imaging(MRI) examination and/or there are&#xD;
                  contraindications for MRI examination, such as prosthesis, orthotics or&#xD;
                  orthodontics, which will interfere with the volume analysis of the target&#xD;
                  Plexiform neurofibroma( PN) on MRI;&#xD;
&#xD;
          -  Patients who need to take more than the recommended dose of vitamin E daily;&#xD;
&#xD;
          -  Patients who have participated within 4 weeks before the first medication and used&#xD;
             other anti-tumor clinical trial drugs or wihtin 5 half-lives;&#xD;
&#xD;
          -  According to the judgment of the investigator, there are situations that seriously&#xD;
             endanger the safety of the patients or affect the completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qingfeng Li, Doctor</last_name>
    <phone>021-2327169</phone>
    <email>dr.liqingfeng@shsmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital, School of Medicine, Shanghai JiaoTong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingfeng Li, Doctor</last_name>
      <phone>021-2327169</phone>
      <email>dr.liqingfeng@shsmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurofibrosarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

